Pacira BioSciences, Inc. provided preliminary revenue guidance for the first quarter of 2022. For the period, the company reported preliminary revenues of $157.4 to $158.4 million for the first quarter of 2022, compared with $119.0 million for the first quarter of 2021. ZILRETTA net product sales are expected to be between $23.0 million and $24.0 million for the first quarter of 2022, compared with $24.6 million for the first quarter of 2021.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
26.1 USD | -2.50% | -4.61% | -22.64% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.64% | 1.21B | |
+27.97% | 672B | |
+23.81% | 550B | |
-7.02% | 351B | |
+14.85% | 317B | |
+6.25% | 292B | |
+2.11% | 211B | |
-0.49% | 203B | |
-10.06% | 194B | |
-11.81% | 144B |
- Stock Market
- Equities
- PCRX Stock
- News Pacira BioSciences, Inc.
- Pacira BioSciences, Inc. Provides Preliminary Revenue Guidance for the First Quarter of 2022